Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVIMMUNE IFCT-1802: Durvalumab in Treatment-Naive ECOG PS 2–3 NSCLC
2018-004742-42Phase 2Active
- Sponsor
- IFCT
- Start
- Apr 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by IFCT. Primary endpoint: Percentage of patients experiencing Grade 3-5 treatment-related adverse events. Started Apr 2019; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-004742-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004742-42.